Tag: antimicrobials

AI4Health CDT Award

AI4Health ICL

Professor Holmes and Dr Georgiou were successfully awarded a UKRI Centre for Doctoral Training in Artificial Intelligence (AI) PhD studentship. The studentship focuses on the development of intelligent, AI-based personalised clinical decision support systems to support and optimise antimicrobial therapy in obese patients with multi-morbidities.

Whilst antimicrobial therapy is often prescribed according to a ‘one dose fits all’ model, individual responses to antimicrobials vary widely, particularly in certain patient groups such as those with multi-morbidities (e.g. obesity or sepsis). The project will build upon our previous NIHR i4i Product Development Award:  Enhanced, Personalised, Integrated, Care for Infection Management at the Point-of-Care award which led to the development of a clinical decision support system to support evidence based antimicrobial prescribing.

Patients with multi-morbidities are often inappropriately treated with antimicrobials due to a lack of evidence to support prescribing decisions. This project will improve patient outcomes through the development a novel decision support system, linking artificial intelligence with data from electronic health records to improve the diagnosis and management of infections in obese patients.

Introducing: Dr. Alaa Riezk

Profile photo
Dr. Alaa Riezk

Dr. Alaa Riezk is a trained Pharmacist. He attained a Masters degree in Microbiology from Damascus University and then completed a PhD degree in Microbiology and Drug Delivery from the London School of Hygiene and Tropical Medicine in 2020.

Recently, Alaa joined Imperial College as a postdoctoral researcher in the Centre for Antimicrobial Optimisation (CAMO) .

Key to CAMO is the development of in-house testing for a selection of antimicrobial drugs, including further development of a minimally invasive biosensor for real-time antimicrobial monitoring. Alaa will be responsible for setting up liquid chromatography-mass spectrometry (HPLC-MS/MS) assays to support these projects within CAMO. To coincide with other projects in the CAMO portfolio, he will initially develop assays for the β-lactams and colistin with scope to expand further as required. Once set up, there will be an ongoing requirement to analyse samples throughout the fellowship. Alaa will also work on the development and clinical testing of our microneedle biosensor project, incorporating closed-loop control of penicillin delivery.